Recursion Pharmaceuticals, Inc.
- Stock
- Ticker RXRX
- Nasdaq
Performance, volatility and drawdowns of Recursion Pharmaceuticals, Inc. since 04/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $1,279. Global equities (VT): $14,653.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −94.1% in 11/2026, measured from the peak in 07/2021. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 4.5 | 15 | 19 | 5.2 | 36 | 6.5 | 7.7 | 19 |
| Gross profit | -8.2 | -7.1 | -0.9 | -9.5 | 21 | -6.0 | -3.8 | 8.5 |
| Operating income | -184 | -191 | -176 | -172 | -108 | -129 | -135 | -123 |
| EBITDA | -171 | -172 | -152 | -151 | -89 | -109 | -117 | -107 |
| Net income | -179 | -202 | -172 | -162 | -108 | -118 | -131 | -119 |
| Earnings per share | -0.57 | -0.50 | -0.41 | -0.36 | -0.17 | -0.22 | -0.25 | -0.22 |
| Balance sheet | ||||||||
| Total assets | 1,449 | 1,305 | 1,302 | 1,400 | 1,474 | 1,340 | 1,213 | 1,222 |
| Liabilities | 414 | 371 | 383 | 353 | 343 | 315 | 298 | 316 |
| Equity | 1,035 | 934 | 919 | 1,047 | 1,131 | 1,025 | 915 | 906 |
| Cash | 594 | 500 | 525 | 660 | 743 | 654 | 546 | 550 |
| Cash flow | ||||||||
| Operating cash flow | -115 | -132 | -76 | -117 | -46 | -81 | -106 | -77 |
| Capital expenditure | -1.3 | -1.8 | -3.2 | -0.2 | -1.2 | -0.3 | 0.0 | -0.4 |
| Free cash flow | -117 | -134 | -80 | -118 | -47 | -81 | -106 | -78 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2023 at +27.9%, weakest 2022 at −55.0%. 1 of 4 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 2 Nov 2026 | −$0.22 |
| 5 Aug 2026 | −$0.25 |
| 6 May 2026 | −$0.22 |
| 25 Feb 2026 | −$0.17 |
| 5 Nov 2025 | −$0.36 |
| 5 Aug 2025 | −$0.41 |
| 5 May 2025 | −$0.50 |
| 28 Feb 2025 | −$0.57 |
| 6 Nov 2024 | −$0.34 |
| 8 Aug 2024 | −$0.40 |
| 9 May 2024 | −$0.39 |
| 29 Feb 2024 | −$0.42 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €1.4bn
- Market cap in trading currency
- $1.53bn
- Enterprise value
- $976m
- P/E
- –
- P/S
- 22.36
- P/B
- 1.68
- EV/Sales
- 14.30
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -20.5%
Results (last four quarters)
- Revenue
- $68.2m
- Gross profit
- $19.9m
- EBITDA
- −$421m
- Net income
- −$476m
- Earnings per share
- −$0.86
- Revenue per share
- $0.11
- Revenue growth
- +258.5%
- Earnings growth
- –
Profitability
- Gross margin
- 29.2%
- Operating margin
- -725.4%
- Net margin
- -697.1%
- Return on equity
- -48.7%
- Return on assets
- -38.9%
Balance sheet and cash flow
- Cash
- $550m
- Cash per share
- $0.88
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 5.01
- Book value per share
- $1.45
- Operating cash flow
- −$311m
- Free cash flow
- −$312m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 623m
- Volume
- 29.7m
- Avg. volume 3 months
- 23.4m
- Relative volume
- 1.2
Price and technicals
- Price
- $2.45
- 1 day
- −9.9%
- 52-week high
- $4.96
- 52-week low
- $2.45
- Distance to 52-week high
- −50.6%
- Distance to 52-week low
- 0.0%
- Distance to 50-day line
- −34.1%
- Distance to 200-day line
- −28.9%
- RSI (14)
- 31
- Volatility 1M
- 94.1%
Performance
- 1 week
- −23.1%
- 1 month
- −31.6%
- 3 months
- −24.6%
- 6 months
- −18.6%
- YTD
- −40.1%
- 1 year
- −39.2%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has RXRX performed since 04/2021?
$10,000 grew to $783 by 20 Nov 2026, which is −36.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is RXRX?
Volatility was 84.5% per year, measured on monthly returns. The largest decline from a peak was −94.1%, with the low in 11/2026.
How does RXRX compare with a broad equity ETF?
Over the same period Global equities (VT) returned +8.2% per year at 14.9% volatility, RXRX returned −36.6% at 84.5%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.